Drug intelligence / Profile preview

AD-223A + AD-223B

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

**AD-223A + AD-223B** is an investigational combination drug therapy currently in clinical studies for the treatment of **essential hypertension**. Both AD-223A and AD-223B are assumed to be small molecule pharmaceutical agents, utilized together for synergistic antihypertensive effect. Specific chemical entities, mechanisms of action, and individual pharmacological properties are not disclosed in the available public sources. This investigational therapy is being evaluated for efficacy and safety in relevant clinical trials for patients with hypertension.

Beyond the preview

Go deeper on AD-223A + AD-223B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-223A + AD-223B.

Explore the full profile